Status:
RECRUITING
Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The study examines the application of expanded natural killer cells (NK cells) following haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) for AML or MDS. Haplo-HSCT is a ...
Eligibility Criteria
Inclusion
- Patient:
- \>18 years of age
- No HLA-matched related or unrelated donor available
- AML or MDS-EB with indication for a haplo-HSCT according to the guidelines of the University Hospital Basel Stem Cell Transplant Team
- Judged by the transplant physicians to have adequate organ function and no contraindications to haplo-HSCT
- Available related haploidentical donor
- Written informed consent
- Donor:
- \>18 years old, haploidentical parent, sibling or other relative
- Donor suitable for cell donation and apheresis according to standard criteria
- Written informed consent
Exclusion
- Patient:
- APL diagnosis
- Presence of relevant (mean fluorescence intensity \>2000) donor-specific anti-HLA antibodies
- Pregnancy
- Necessity of immunosuppression apart from GvHD prophylaxis
Key Trial Info
Start Date :
November 12 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03300492
Start Date
November 12 2018
End Date
December 31 2026
Last Update
December 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel
Basel, Switzerland, 4031